BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
T. Rowe Price Investment Management, Inc. reports holding 4,246,706 shares of BioLife Solutions common stock, representing 8.9% of the class. The filing is a Schedule 13G filed by an investment adviser (classification IA) and indicates sole voting and sole dispositive power over those shares. The filer certifies the securities were acquired and are held in the ordinary course of business and states they were not acquired to change or influence control of the issuer. The filing also includes a declaration denying beneficial ownership in a closing certification.
Casdin-related reporting persons disclosed beneficial ownership of 7,207,165 shares of BioLife Solutions, Inc. That stake represents 15.0% of the company based on 47,905,265 shares outstanding as of July 31, 2025. The filing names Casdin Capital, LLC; Casdin Partners Master Fund, L.P.; Casdin Partners GP, LLC; and Eli Casdin as the reporting persons.
The filing states the Fund used its working capital to purchase the shares and did not use borrowed funds except for ordinary working capital borrowing. The Reporting Persons say they currently have no plans to change board composition, management, capitalization or dividend policy but reserve the right to propose or effect such changes and to engage with management and other shareholders about maximizing shareholder value.
Casdin Partners Master Fund, L.P. reported an insider sale of BioLife Solutions, Inc. (BLFS) common stock on 08/11/2025. The filing shows a reported sale of 500,000 shares at a price of $22.60 per share. The transaction is recorded with transaction code S indicating a disposition.
The filing identifies related reporting entities—Casdin Capital, LLC; Casdin Partners GP, LLC; and Eli Casdin—and states the securities are owned directly by the Master Fund and may be indirectly beneficially owned by those entities. After the reported transaction the reporting persons are shown as beneficially owning 7,207,165 shares indirectly.
BioLife Solutions (BLFS) Form 144 discloses a proposed sale of 500,000 shares of common stock through BMO Capital Markets on NASDAQ with an aggregate market value of $11,185,000. The filing reports 47,905,265 shares outstanding and an approximate sale date of 08/11/2025.
The shares were acquired on 12/16/2020 by purchase from a shareholder and paid in cash. The filing also lists a recent sale by Casdin Partners Master Fund, L.P. of 1,000,000 shares on 06/10/2025 for $23,800,000. The seller certifies they are unaware of any undisclosed material adverse information.
BioLife Solutions Inc. (BLFS) – Form 4 filing: Chief Human Resources Officer Sarah Aebersold sold 198 shares of common stock on 7 July 2025 at $22.27 per share under a pre-established Rule 10b5-1 trading plan. The sale was executed to cover tax-withholding obligations associated with previously vested restricted stock. After the transaction, the officer still owns 78,523 shares, which continue to be held directly. No derivative security activity was reported.
The transaction represents <0.3% of the insider’s total direct holdings and does not indicate a change in her overall investment thesis or role at the company. As such, the filing is considered routine and of low financial materiality for most investors.